Tag:
John P. Longenecker
Latest Headlines
Latest Headlines
Favrille dumps Specifid after trial failure
San Diego-based Favrille has halted development of Specifid, a treatment for follicular B-cell non-Hodgkin's lymphoma. In a Phase III trial the drug failed to show a statistically significant
